Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.Statement On A Nonproprietary Name Adopted…
Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association It targets IL-23.
This drug was developed by MedImmune, LLC.
References
Gebaseerd op: Wikipedia — Brazikumab · auteursgeschiedenis.
Tekst: CC BY-SA 4.0.
Wikisyntaxis en sjablonen zijn verwijderd; langere teksten zijn ingekort.